Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., as Chief Medical Officer

CHAPEL HILL, N.C., Sept. 11, 2013 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the appointment of Shi Yin Foo, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Foo, who has broad experience in the development of cardiovascular drugs and translational medicine, is well positioned to help Cardioxyl realize the potential of its nitroxyl (HNO) technology for the treatment of patients with serious cardiovascular disease.

Dr. Foo joins Cardioxyl from Novartis, where she was responsible for the establishment and execution of multiple novel programs in heart failure and the cardiorenal space, and is a named inventor on several associated patents applications. She has served as clinical and translational medicine reviewer for numerous studies spanning the full spectrum of Phase I to Phase III clinical trials. Through her experience in both industry and practice, Dr. Foo has developed deep expertise in both acute and chronic heart failure.

"We are very pleased to welcome Dr. Foo to Cardioxyl as our CMO," said Chris Kroeger, M.D., Cardioxyl's President and Chief Executive Officer. "Her unique combination of both early- and late-stage cardiovascular development experience combined with her extensive clinical experience in the treatment of patients with heart failure will serve as an excellent complement to Cardioxyl's proprietary expertise in the biology, physiology and chemistry of nitroxyl donors."

Dr. Foo previously was an Assistant Physician in Medicine, Division of Cardiology at Massachusetts General Hospital in Boston, where she served as an attending physician in heart failure/transplantation. Her research focused on the effects of diet on endothelial stem cells and on novel biomarkers to identify these stem cells in vivo. She received the GSK Cardiovascular Foundation Young Investigator Award for this work.

Dr. Foo obtained her M.D. and Ph.D. in Immunology at Stanford University and her MMSc in the Clinical Investigator Training Program at Harvard Medical School. She also holds a B.A. in Molecular, Cellular and Developmental Biology from Princeton University. Dr. Foo was a clinical fellow in Cardiology with subspecialty training in Heart Failure/Transplantation at Massachusetts General Hospital, where she was a winner of the Roman DeSanctis Clinical Scholar Award for clinical expertise. She is board-certified in Internal Medicine and in Cardiovascular Medicine.

"Cardioxyl's nitroxyl donor candidates are supported by remarkable biology, and demonstrate the potential for profound clinical benefit in an under-served patient population," said Dr. Foo. "The Cardioxyl pipeline provides a truly unique opportunity to improve the health and quality of life for patients with heart disease."

About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.

SOURCE Cardioxyl Pharmaceuticals, Inc.